

CONTENTS

CONTRIBUTORS	xiii
PREFACE	xvii

An Introduction to Dyskinesia—the Clinical Spectrum

AINHI D. HA AND JOSEPH JANKOVIC

I. Introduction	1
II. Akathisia	2
III. Ballism	3
IV. Chorea	3
V. Dystonia	4
VI. Jumpy Stumps	7
VII. Levodopa-Induced Dyskinesias	7
VIII. Assessment of Dyskinesia	12
IX. Moving Toes and Moving Fingers	13
X. Myoclonus	13
XI. Myokymia	14
XII. Myorhythmia	14
XIII. Stereotypy	15
XIV. Tardive dyskinesia	15
XV. Tics	17
XVI. Tremor	19
XVII. Conclusion	20
References	22

L-dopa-induced Dyskinesia—Clinical Presentation, Genetics, and Treatment

L.K. PRASHANTH, SUSAN FOX AND WASSILIOS G. MEISSNER

I. Introduction	32
II. Historical Aspects	32
III. Epidemiology	33
IV. Risk Factors	34
V. Genetics of Dyskinesia	35

VI. Classification	36
VII. Clinical Characteristics	38
VIII. Treatment	40
References	47

Experimental Models of L-DOPA-induced Dyskinesia

TOM H. JOHNSTON AND EMMA L. LANE

I. Historical Development of a Model of L-DOPA-Induced Dyskinesia	56
II. MPTP-Lesioned Primate Model of L-DOPA-Induced Dyskinesia	57
III. Unilateral 6-OHDA Lesioned Rodent Model of L-DOPA-Induced Dyskinesia	70
IV. Critique of Toxin-Based Models of L-DOPA-Induced Dyskinesia	75
V. Alternative Models of L-DOPA-Induced Dyskinesia	77
VI. Future Modeling of L-DOPA-Induced Dyskinesia	78
VII. Conclusions	79
References	79

Molecular Mechanisms of L-DOPA-induced Dyskinesia

GILBERTO FISONE AND ERWAN BEZARD

I. Introduction	96
II. Basal Ganglia and Medium Spiny Neurons	97
III. LID and Hyperactivity of D1R/cAMP Signaling	98
IV. Increased ERK Signaling in LID: Transcriptional and Translational Changes	102
V. Glutamate NMDA Receptors and LID	105
VI. mGluR5	106
VII. Controlling Dyskinesia by Acting on the MSNs of the Indirect Pathway	106
VIII. Cannabinoid CB1 Receptors	109
IX. Pre-Synaptic Mechanisms: Serotonin Receptors	109
X. Conclusions	111
Acknowledgments	112
References	112

New Approaches to Therapy

JONATHAN BROTCHE AND PETER JENNER

I. Introduction	124
II. Factors that Control the Priming and Expression of LID	125
III. Modifying LID Through Dopaminergic Approaches	127
IV. Nondopaminergic Approaches to LID	134
V. Conclusions	143
References	143

Surgical Approach to L-DOPA-induced Dyskinesias

TEJAS SANKAR AND ANDRES M. LOZANO

I. Introduction	151
II. Brief Overview of LID	152
III. Surgical Treatment of LID: Efficacy and Mechanisms of Action by Target	156
IV. Surgical Approach to the Patient With LID	162
V. Conclusion	165
References	165

Clinical and Experimental Experiences of Graft-induced Dyskinesia

EMMA L. LANE

I. Introduction	173
II. Transplantation for Parkinson's Disease	174
III. The Clinical Phenomena of GID	175
IV. Animal Models of GID	171
V. Understanding the Cause of GID	178
VI. Strategies for Dealing with GID	181
VII. Final Considerations	182
Acknowledgments	182
References	183

Tardive Dyskinesia: Clinical Presentation and Treatment

PETER N. VAN HARTEN AND DIEDERIK E. TENBACK

I. Introduction	188
II. Clinical Features	190
III. Differential Diagnosis	192
IV. Pathophysiology	194
V. Tardive Dyskinesia Treatments	197
VI. Prevention and Treatment of Tardive Dyskinesia in Clinical Practice	201
VII. Conclusion	204
References	204

Epidemiology and Risk Factors for (Tardive) Dyskinesia

DIEDERIK E. TENBACK AND PETER N. VAN HARTEN

I. Introduction	212
II. Spontaneous Dyskinesia in Psychiatry	213
III. Discussion	219
IV. Conclusion	225
Acknowledgment	226
References	226

Genetics of Tardive Dyskinesia

HEON-JEONG LEE AND SEUNG-GUL KANG

I. Introduction	232
II. Genes Involved in Pharmacokinetics	234
III. Genes Involved in Pharmacodynamics	238
IV. Oxidative-Stress-Related Genes	245
V. Other Genes Reported to be Associated with TD	247
VI. The Genome-Wide Association Approach	249
VII. Future Research: Copy-number Variations and Epigenetics	250
VIII. TD as a Phenotype	252
IX. Conclusion	253
Acknowledgment	253
References	254

Animal Models of Tardive Dyskinesia

SHRINIVAS KRISHNARAO KULKARNI AND ASHISH DHIR

I. Introduction	265
II. Limitations	284
III. Conclusion	284
References	284

Surgery for Tardive Dyskinesia

STÉPHANE THOBOIS, ALICE POISSON AND PHILIPPE DAMIER

I. Introduction	289
II. Lesioning Surgery	290
III. Deep Brain Stimulation	292
IV. Conclusion	294
References	294

Huntington's Disease: Clinical Presentation and Treatment

MARIANNE J.U. NOVAK AND SARAH J. TABRIZI

I. Clinical Presentation and Genetics	298
II. The Clinical Phenotype and its Management	305
III. The Atypical Phenotype, including Juvenile Huntington's Disease	318
IV. Advanced Disease and End of Life Issues	319
V. Looking to the Future: Research into New Treatments for Huntington's Disease	320
VI. Conclusions	320
References	321

Genetics and Neuropathology of Huntington's Disease

ANTON REINER, IOANNIS DRAGATIS AND PAULA DIETRICH

I. Introduction	326
II. The HD Gene	327
III. Normal CAG Repeat Length	329
IV. CAG Repeat Length and Disease Onset and Progression	329
V. CAG Repeat Instability	330
VI. Genetic Modifiers of CAG Repeat Instability	330
VII. Genetic Modifiers of HD Age-of-Onset	331
VIII. HD: A True Dominant Gain-of-Function Disorder?	333
IX. Expression of Huntingtin in Normal and HD Human Brain	334
X. HD Brain Pathology and the Vonsattel Grading System	337
XI. Basal Ganglia Pathology in HD	339
XII. Other Telencephalic Areas in HD	349
XIII. Brainstem Areas in HD	351
XIV. HD and Neurogenesis	353
XV. Neuroinflammatory Neuropathology in HD	354
Acknowledgments	354
References	354

Pathogenic Mechanisms in Huntington's Disease

LESLEY JONES AND ALIS HUGHES

I. Introduction	374
II. The <i>HTT</i> Gene Product	374
III. The Mutant Htt Protein and its Downstream Effects	386
IV. Conclusions	398
References	398

Experimental Models of HD And Reflection on Therapeutic Strategies

JINHO KIM, OLIVIA L. BORDIUK AND ROBERT J. FERRANTE

I. Introduction	420
II. Mouse Models of HD	423
III. Methodological Considerations for Mouse Therapeutic Trials	436
IV. Existing Clinical Management	441
V. Mechanisms of Cell Death and Potential Therapeutic Targets in HD	442
VI. Conclusion	462
Acknowledgments	463
References	463

Cell-based Treatments for Huntington's Disease

STEPHEN B. DUNNETT AND ANNE E. ROSSER

I. Introduction	483
II. Present Status	485
III. Future Developments	496
IV. Conclusion	500
Acknowledgments	501
References	501

Clinical Phenomenology of Dystonia

CARLO COLOSIMO AND ALFREDO BERARDELLI

I. Historical Review	509
II. Definition and Classification	510
III. Clinical Features in Different Subtypes of Focal and Segmental Dystonia	515
IV. Neuropsychiatric Features of Dystonia	520
V. Conclusions	521
References	521

Genetics and Pharmacological Treatment of Dystonia

MATTHEW J. BARRETT AND SUSAN BRESSMAN

I. Primary Torsion Dystonia	526
II. Dystonia-Plus Syndromes without Brain Degeneration	535
III. Dystonia as a Feature of Degenerative Genetic Syndromes	538
IV. Treatment of Dystonia	540
References	542

Experimental Models of Dystonia

ANNALISA TASSONE, GIUSEPPE SCIAMANNA, PAOLA BONSI,
GIUSEPPINA MARTELLA AND ANTONIO PISANI

I. Introduction	552
II. Models of Genetic Engineering	553
III. Spontaneous Mutants	559
IV. Pharmacological and Neural Lesion Models	561
V. Conclusions	565
References	566

Surgical Treatment of Dystonia

JOHN YIANNI, ALEXANDER L. GREEN AND TIPU Z. AZIZ

I. Background	574
II. Classification	575
III. Medical Treatment of Dystonia	576
IV. Surgical Treatment of Dystonia	577
V. Deep Brain Stimulation (DBS) for Dystonia	578
VI. DBS for Dystonia—Clinical Overview	581
VII. Conclusion	586
References	586
INDEX	591
CONTENTS OF RECENT VOLUMES	607